Earlier this year, we shared how Park member Cambridge Heartwear launched its groundbreaking HeartSense® wearable, a world first medical grade ECG device designed and developed at Cambridge Science Park.
Now, the company has reached another major milestone.
Cambridge Heartwear has secured a place on an NHS Supply Chain framework worth up to £184 million, enabling NHS Trusts, government organisations and private healthcare providers across the UK to purchase its HeartSense® technology over the next four years.
The agreement represents a significant commercial step for the University of Cambridge spin out and reflects growing confidence in technology developed at Cambridge Science Park.
HeartSense® is designed to support earlier detection of heart conditions such as atrial fibrillation, helping clinicians identify patients sooner and reduce the risk of serious cardiovascular events, including strokes and heart attacks.
Founded by Professor Rameen Shakur, Cambridge Heartwear develops its engineering, software and AI at Cambridge Science Park while manufacturing remains in the UK. Following UKCA clearance in 2025 and official Made in Britain accreditation, the company is now preparing for international expansion with US FDA approval underway.
Professor Shakur said: “After ten years of finessing HeartSense®, I’m delighted to see our technology being adopted by the NHS. Our device delivers faster results as we work to prevent strokes and heart attacks through early diagnosis. It’s another Cambridge idea gone big, built from engineering and AI patents developed within the University.”